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ABSTRACT  
 
This paper presents and discusses schemes of prevention measures in public health. A 
mathematical model is purposely designed to outline various features related to cost issues and a  
numerical application to Italian cancer data is used to show the flexibility and utilization of the model.   
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1. INTRODUCTION AND MOTIVATION 
 
Whatever be the health system structure, public-based,  or based on a public-private 
partnership, embedded prevention issues are becoming more and more crucial in a 
long-term perspective of cost reductions and optimal resource management. Several 
studies in the literature (based on standard statistical modelling or developping original 
mathematical approaches) provide specific, disease-related analysis of the impact of 
prevention measures on various public health and socio-demographic aspects of 
community life (see, among many: Boily et al., Goldie S. et al., Zethraeus N.) however, 
very few of them single out the general economic impact on public health expenditure 
budget in a comprehensive model-theoretical approach (see, for instance, Davies R. et 
al., Haddix A. et al., Mackinnon D. and Dwyer J.). 
This paper presents a general mathematical model of the effects of prevention 
strategies on health care global costs, when patients are classified at various stages of 
severity of a disease under study. In fact, illness severity, risk exposure and diagnostic 
delay are often factors that increase the costs of care: effective prevention strategies 
can greatly contribute to cost reductions and/or optimization of the care delivery 
systems. 
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The model is based on an underlying, evidence-based staging of the disease of 
interest. This preliminary structure is designed to further accommodate issues such as 
competing costs between care and prevention and the related expenditure policy 
measures. 
 
 
 
2. THE GENERAL PREVENTION MODEL 
 
Let ppP   be the total number of individuals in a population, divided into p 
individuals affected by some disease under study at n increasing levels of severity, 
and p  healthy individuals, and let i  ni ,,1  be the known prevalences of each 
level of severity of the disease in the population. 
A public health system that must treat all affected individuals has a total, disease-
related cost C  given by 
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where 0A  is a general fixed system cost and nii ,,1,   are the variable treatment 
costs per affected individual and related to the n levels of severity of the disease. Note 
that the distribution of individuals in (1) is supposed to be induced by the disease 
symptomatology: i.e., affected individuals enter the cost function (1) at a level 
corresponding to detectable symptoms. 
Possible prevention measures can be thought of as some form of screening over the 
entire population P to detect all affected individuals before their disease becomes 
symptomatic (i.e., at a lower level of severity). Let e be the unit cost of the prevention 
operations; the total cost of prevention is therefore given by 
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and the prevention cost per affected individual actually detected is then given by 
 
 
  
 
 
4 
 















n
i
i
n
i
i
e
P
P
e
11
1

      (2) 
 
 
The effects of prevention on the number of affected individuals are thus given by 
their redistribution among the n levels of severity (with the corresponding changes in 
the treatment costs) according to a lower triangular transition matrix  
njiij ...1; 
 Π  
such that: 
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where the expressions in (2) are trivially generated by the hypotheses that the disease 
prevalence does not changes within the time horizon considered and that prevention 
measures do not interact with the symptomatology of the disease (i.e.: the level of 
severity detected by prevention measures cannot be higher than the level 
corresponding to detectable symptoms). 
By using (3), the estimated total system cost, when prevention measures are put in 
place, is thus given by 
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where the variable treatment cost of the i-th level of severity is now given by the 
algebraic sum of 
 
 Pii : the cost of individuals detected at symptomatic level of severity; 
 

n
ij
jjii P
1
 : the cost of individuals detected at the i-th level of severity 
with a higher symptomatic level of severity; 
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 
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1
1
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iiji P : the cost of individuals with i-th symptomatic level of severity 
detected at a lower level of severity; 
 

n
ij
jji P
1
 : the prevention costs per individual with i-th symptomatic 
level detected at a lower level of severity. 
  
For the prevention measures to induce a saving S in the budget of the system, the 
following positivity condition must be met 
 
0ˆ  CCS       (5) 
 
which, by using (1) and (4), becomes 
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By reordering and inverting the indexes of the second term of left hand side, 
condition (6) becomes 
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and solving for :  
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Thus an economically sound prevention policy can be effectively set up when the 
cost of one asymptomatic detected individual is smaller than the average cost 
reduction, weighed by the newly detected prevalences of each level of severity. Now, 
using (2), (7) can be expressed in terms of the unit cost e of prevention operations: 
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In the absence of further, specific information on the morbidity of the disease under 
study at various levels of severity (i.e.: no direct or indirect information available on the 
ij  terms), the hypotheses that the whole population P undergoes the prevention 
screening and that no biased error occurs during the screening operation, provide a 
reasonable ground to the conservative hypothesis that the prevalence rates i  
ni ,,1  of the general population also apply to the various levels of severity. This 
implies that all transitions ij can be approximated by the corresponding prevalence 
rates niijj ,,1,     and the second of (8) becomes 
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3. CANCER AND PREVENTION COSTS IN ITALY. A NUMERICAL EXAMPLE 
 
The various cancer forms are a typical example falling into most of the modelling 
hypotheses as in section 2; even when they may be limited to any incidence sub-
populations, these may, however, be easily detected (male-female, for instance). In 
the following, an example of the model-at-work is presented, using cancer treatment- 
and cost-data derived from external studies. 
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As of (9), relevant data consist of prevalences and cost distributions at various 
stages of severity of the disease; these input data are compared to the expenditure 
limit computed through (9) and mapped onto graphical representations. 
For the sake of homogeneity of the various primary tumors and to outline the use of 
the model the staging classifications have been reduced to 3 for each type of tumor. 
Moreover, the cost scaling between stages was supposed to amount to: 
123 42    throughout, as the costs of single stagings are not immediately 
available.  
 
Table 1. - Expenditure limits by tumor primary site and related costs and epidemiology. 
 
primary prevalence%* unit cost (×1000)** limit 
lung 0,17 36 53 
stomach 0,12 19 18 
melanoma 0,27 21 40 
colon/rectum 0,69 24 162 
cervix 0,05 10 5 
breast 2,26 17 596 
prostate 1,23 19 192 
leukemias 0,09 77 56 
 
* A.I.R.TUM. – I tumori  in Italia  (2012) - http://www.tumori.net 
** CENSIS, from Economist Intelligent Unit (2010) 
 
Figures 1 and 2 show the mapping of the model expenditure limit (as in 9) to, 
respectively, the desease prevalence and the average treatment cost, while figure 3 
relates the unit treatment cost to prevalence. A visual inspection of the three figures 
shows, as expected, a clear dependence of the model expenditure limit from the 
pathology prevalence. On the other hand, no evident dependency is exhibited between 
unit treatment cost and prevalence (Fig. 3) and unit treatment cost and pathgology 
prevalence (Fig. 2). 
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FIGURE 1. – Tumor primary sites by prevalence and prevention 
expenditure limit (Table 1) 
 
FIGURE 2. – Tumor primary sites by unit treatment cost and 
prevention expenditure limit (Table 1) 
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FIGURE 3. – Tumor primary sites by prevalence and unit 
treatment cost (Table 1) 
 
 
Preliminary results from this simple numerical application highlight the roles of unit 
treatment cost and of the disease prevalence in the definition of the prevention 
expenditure limit. In fact, while the unit cost enters (9) only as a cost redistribution 
among classes of severity and, therefore, as a relative (not absolute) budget savings, 
the disease prevalence is what actually provides a larger probability to detect an 
affected individual and thus a larger probability of not wasting prevention resources in 
the search of an unlikely event. 
 
4. THE GEOMETRY OF PREVENTION 
 
By defining the vectors  
nii ,,1
 β  and  
nji ,,1 α  and the Hollow matrices 
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where nI  is the nn  identity matrix, (9) can be re-written as  
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where n1  is the n-vector with elements all equal to 1’s. Note also that 2B  is skew-
symmetric and both 1B  and 2B  are known as generalized Conference matrices. 
From (10) direct, a geometric interpretation of the upper limit to prevention unit 
expenditures can be drawn in terms of prevalences and treatment costs. In fact, 
vectors α , β  and n1  represent, respectively, the treatment cost profile of the disease 
under study, the prevalence profile and the profile of an unscreened individual; 
therefore the degenerate, bilinear forms in (10) map, respectively, a prevalence profile 
and an unscreened individual onto the cost space, the degenerate condition 
accounting for the condition in (5). 
This vector setting of the prevention expenditure limit (9) may be effectively used, by 
direct modifications of β  and n1 , to accomodate complex prevention schemes, such 
as selections of risk group sub-populations and communicable (infectious or 
hereditary) diseases. In these cases we can introduce such modifications to the 
vectors as, for instance, 
 
 risk groups: ),,,( 21 nn rrr  r1  may be the hazard ratios of n exposed sub-
populations 
 group survival: ),,,( 21 nn LLL L1  is the cost-adjusted, expected total 
life span of patients at various levels of severity 
 infectious diseases:    )(,),(),( 002010 RsRsRsR nn  s1  is the scalar field 
of secondary cases as a function of the basic reproduction number, via an 
epidemic model or external epidemiological studies 
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5. FINAL REMARKS AND FURTHER DEVELOPMENTS 
 
The model here presented is based on health care hypotheses that apply to most 
public health schemes. Moreover, current ethical and social issues have no part in the 
approach here presented. The model is flexible enough to be further extended as to 
include more complex issues as shown in the previous section. It is, however, 
interesting to notice that the matrix form expressions (10) allow for a geometrical 
interpretation of the prevention structure: in fact, the bilinear forms in (10) are 
degenerate (the matrices B1 and B2 are singular), thus mapping the unit n-vector 
(representing a non-informative individual) onto the (n-1)-space of treatment unit 
costs, where the reduction of dimensions is due to the fact that only non-zero cost 
differences are considered. This amounts to representing an unsorted (non-
informative), affected individual in terms of cost reduction if positively sorted by some 
forms of prevention/screening for the disease under study. Any further improvement to 
this model can, therefore, be attained by new geometrical definitions of the space of 
individuals, of the space of treatment costs or a combination of both, so as to possibly 
include targeted prevention measures and/or selective treatment costs. 
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